Group items tagged

Nearly 70 years ago the UK Government recognised the imbalance of power between commercial landlords and tenants and passed the Landlord and Tenant Act 1954 (the Act), giving most commercial tenants a right of security of tenure. What is security of tenure? The Act grants tenants of business premises (so this would include pharmacy tenants) the right when the fixed term of their lease has ended to remain in occupation of the premises and the right to apply for the grant of a new lease. The landlord can only object to the grant of the new lease of the premises to the tenant, and therefore regain possession of the property on certain grounds set out in the Act. The parties to a lease can contract outside the provisions of the Act and where this is the case, a tenant would not have security of tenure. Most landlords will insist on no security of tenure where a lease is granted for a short term. As pharmacy leases have tended to be granted for longer terms (usually between 10 and 15 years) pharmacy tenants often have security of tenure. The Act sets out strict procedures which need to be followed to both contract outside the provisions of security of tenure and also to exercise the security of tenure rights granted by the Act. Pharmacists should take legal advice before agreeing to a pharmacy lease being excluded from the Act, and also at the end of their lease term whether or not they have security of tenure. If the lease is contracted outside of the Act, advice should be sought on agreeing new lease terms, if the pharmacist wishes to remain, as there will be no right to do so beyond the end of the lease term. If the lease is protected by the security of tenure provisions of the Act, advice should still be sought, as the Act prescribes a formal notice procedure that both the landlord and tenant must adhere to, before a new lease can be granted.

International day for persons with disabilities on 3rd December - Note on schemes for the welfare of persons with disabilities and concessions available to them. The Government of India is committed for the realization of full participation, protection of rights, and equal opportunities to all including persons with disabilities. India is a country where most of the population lives in the rural areas and accessing the health and rehabilitation services has always been a challenge. In a Backgrounder issued yesterday, a brief summary of the major steps initiated by the Ministry of Social Justice & Empowerment in this direction were given. Following is the Background Note on the legislative and Institutional framework along with the major schemes of the Ministry of Social Justice & Empowerment for the welfare of the People with Disabilities (PwDs). The Note also contains information on facilities and concessions available to PwDs under other central schemes which are being run by other Union Ministries. OFFER ON INTERNATIONAL DISABILITY DAY Wheelchair @ 4499 INR Tricycle @ 6500 INR Legislative Framework: There are four important legislations dealing on disabilities issues- The Persons with Disabilities (Equal Opportunities, Protection of Rights and Full Participation) Act, 1995, has laid the foundation of recognition of rights for Persons with Disabilities and has facilitated development of specific programmes for their education, rehabilitation, employment, non-discrimination and social security. The Rehabilitation Council of India Act, 1992 regulates and monitors training of rehabilitation professionals and personnel. The National Trust for the welfare of Persons with Autism, Cerebral Palsy, Mental Retardation and Multiple Disabilities Act, 1999, aims at enabling and empowering persons with disabilities to live independently as fully as possible in their community. Mental Health Act, 1987, address to the specific needs of persons with ment

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

Facilities For Disabilities In India Under Disability Act of 1995 India's Disability Act of 1995 provides various facilities for both children and adults with disabilities in India. Under the Disabilities Act of India, children with disabilities have the right to free education until they reach the age of eighteen in schools that are integrated, or in 'special,' schools. Children with disabilities have the right to appropriate transportation, removal of architectural barriers, as well as the restructuring of curriculum and modifications in the examination system. Scholarships, uniforms, books, and teaching materials are all provided to children with disabilities for free in India. Children with disabilities in India have access to special schools that are equipped with vocational training facilities, and non-formal education. India provides training institutions for teachers in order to establish manpower. Parents of children with disabilities in the nation can move to an appropriate court for the redress of grievances in regards to their children with disabilities; Mobility Products for Handicapped. Parents of children with disabilities in India are required to obtain a, 'disability certificate,' in order to access the facilities mentioned above; they can obtain this certificate from their nearest government hospital, where an Identity Card from the, 'Office of the Commissioner for Disabilities,' will issue it. People in rural areas can obtain this Identity Card from their Block Development Officer's Office (BDO). Side Wheel Attachment for Activa Recent Disability Figures in India: At least 1.2 million people with disabilities in India are living in households consisting only of people with disability. While the total people with disabilities increased by just over 22 per cent over a decade, from almost 22 million in the Census 2001 to 26.8 million in 2011, the number of people with disabilities living on their own has nearly doubled, jumpin

The Equality Act (which replaced the Disability Discrimination Act in 2010) is often cited as a reason for supplying medicines in a compliance aid. This is a complex piece of legislation, but, in essence, provides a statutory duty on businesses to make "reasonable adjustments" in relation to the service that they provide to take into account any relevant disability of a service-users. This statutory obligation might include the provision of a compliance aid where a patient would be at a "substantial disadvantage" without. However, the need to provide medicines in a compliance aid under the Equality Act needs careful consideration and is a balancing exercise. The NHS Terms of Service for community pharmacies in England state that medicines should be provided in original packs save in certain circumstances, which include because of patient needs.

The Department of Health and Social Care (DHSC) has finally published its response to the 2022 consultation on hub and spoke dispensing. Considering the consultation evidence and further discussions, the government has expressed its intention to progress the proposals for enabling hub and spoke models across different legal entities as soon as possible. This will be achieved by using the enabling powers outlined in Part 2 of the Medicines and Medical Devices Act 2021 (MMDA) to amend the Medicines Act 1968 and the HMRs. Furthermore, the DHSC has decided to proceed with the implementation of the two models of hub and spoke dispensing that it consulted on. The government response to the consultation reads: "Having considered the responses, the government intend to proceed to implement the necessary changes to medicines legislation to remove the current restrictions that prevent the hub and spoke dispensing models from operating across different legal entities found in section 10 of the Medicines Act 1968.

As the pharmacy profession continues to evolve, the role of Accredited Checking Technicians (ACTs) is becoming increasingly vital. Anne Ausden, the Deputy Manager of Jephsons Pharmacy, embodies this shift. With over 18 months in her current role, Anne oversees the pharmacy's daily operations, optimises medication use, and ensures high-quality patient care. Her work extends beyond the dispensary, offering blood tests, blood pressure monitoring, flu vaccines, and health education sessions. Anne, a 2023 Pharmacy Business Awards winner, shares her insights on the expanding role of ACTs with Pharmacy Business reporter Rudra Mulmule, particularly in light of recent legislative changes that allow pharmacy technicians to now administer medicines under a Patient Group Direction (PGD) and with the introduction of the Accuracy Checking Pharmacy Technician (ACPT) programme.

All companies must send their accounts to Companies House each year. Recent evidence suggests that UK companies are increasingly struggling to file their accounts on time, with around 213,000 private companies reportedly missing their deadline in 2019-2020, resulting in over £93 million of penalties being issued. Over a fifth of companies that filed their accounts late that year had also filed late in the previous year. Under the Companies Act 2006 ("the Act"), the deadline for private companies to file their annual accounts is nine months from the end of the accounting reference period. There are slightly different rules for filing your first set of annual accounts and if these cover a period of more than 12 months, you must deliver them to Companies House within 21 months of the date of incorporation or 3 months from the accounting reference date, whichever is longer. Not filing your accounts at Companies House in a timely manner is also a criminal offence (under section 451 of the Act) and directors can be personally fined in the criminal courts. It is likely to come as a shock to most company directors who receive a summons to attend the Magistrates' Court in Cardiff for a criminal prosecution, particularly directors in larger pharmacy companies where directors are often detached from the preparation of accounts and senior financial staff and accountants are instructed to take care of such matters.

Customs officials at Mundra port in Gujarat's Kutch district, India, recently seized approximately 6.8 million Tramadol tablets valued at Rs 110 crore (around GBP 10.2 million). The tablets were discovered in two export containers bound for Sierra Leone and Niger in West Africa. Tramadol, an opioid pain medication, was classified as a psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act (NDPS Act) in 2018 and its export is now restricted. This synthetic opioid drug has gained notoriety in recent times as the "Fighter Drug" after it was reported that ISIS fighters used it to stay awake for long hours, said a PIB release on Monday. It is reportedly in high demand in African nations like Nigeria, Ghana, etc. The Mundra Customs seizure is one of the largest seizures of Tramadol since it was notified under the NDPS Act, said the release.

A winter NHS crisis is inevitable unless the government acts now to reverse the worrying decline in community pharmacies. Years of government underfunding could see 3,000 pharmacies in England - around a third of the network - having no option but to shut their doors to patients in the next few years. That figure is based on independent assessments from Ernst & Young and UCL/LSE healthcare professors: it is not scaremongering - it is the reality the country faces. Fifty per cent of pharmacies are already in financial distress because government funding has been falling in real terms since 2019 and that figure is predicted to rise to 75 per cent within the next two years. The government needs to act now and invest in pharmacy or sleepwalk into a healthcare disaster as we have seen with access to dentistry care. Prescription volumes have risen consistently year-on-year by roughly 2 per cent which means fewer pharmacies doing more work and under greater pressure than a decade ago. Ten years ago around 11,200 pharmacies in England were dispensing roughly 79,000 prescriptions; nowadays around 11,500 are dispensing roughly 89,000 prescriptions. The secretary of state recently asked pharmacy to do more to avoid a winter NHS crisis and at the same time said there will be no new money to pay for those additional services. This at a time when the network is in decline with random unplanned pharmacy closures - 640 closures since 2016 - and pharmacy staff face huge workload pressures as prescription demand is increasing year-on-year. The government's approach to pharmacy literally does not add up: the pharmacy contract is not fit-for-purpose now let alone dealing with a NHS winter crisis.

The Royal Pharmaceutical Society (RPS) has called for a 'firm commitment' to prosecuting those making profits through the sale of DNP (2,4-Dinitrophenol). It has also urged the social media companies to 'remove content promoting or selling DNP to further reduce harm'. Legislation to regulate DNP will come into effect on 1 October 2023. On Monday (23 January) it was announced that DNP will be included in the 1972 Poisons Act. President of RPS Professor Claire Anderson said: "DNP is unfit for human consumption and its main use is in the manufacture of explosives and pesticides. It is sold by unscrupulous dealers to vulnerable individuals wanting to lose weight but has a dangerous effect on the metabolism and has led to 32 deaths since 2007 in those taking it as a 'diet drug'. "Including DNP in the Poisons Act is a positive move as it will restrict its availability, but what's really needed is an outright ban to reduce the risk to the public. Australia has already classified DNP as a substance of such a danger to health as to warrant prohibition of sale and we'd like the UK to follow suit.

Two dozen parliamentarians from across the political spectrum have called on the prime minister to act as a wave of pharmacy closures in recent years has threatened to spiral out of control. A letter to the prime minister signed by 24 MPs and peers has warned that worse could be yet to come after "spiralling business costs" and "year after year of real terms funding cuts" have led to hundreds of pharmacy closures. New data from the PSNC shows that over 639 local pharmacies have been lost in England since 2016. "This is the equivalent to just short of one pharmacy closure per constituency", the cross-party group warned. The letter comes as MPs came together at a parliamentary summit to call for pharmacies to be embraced as a "game-changer" for tackling healthcare backlogs and taking pressure off other areas of the NHS. A 'Future of Pharmacy' event was attended by 53 parliamentarians on July 5 in the Palace of Westminster. At the event parliamentarians heard directly from frontline pharmacists and representatives of pharmacy bodies where a map of constituency-specific pharmacy numbers was also unveiled, with details of the number of pharmacy closures in MPs' local area.

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

Northern Ireland's health minister Robin Swann has condemned the act of violence experienced by pharmacy teams, stating such acts "will not be tolerated." His statement follows an ugly incident that took place on Saturday (March 5) at the Teagues Pharmacy, Antrim Road in Belfast, Northern Ireland. Conor McAreavey from Teagues Pharmacy told the BBC that on Saturday a man entered the shop at about 17:30 GMT and used a hammer to break through a Covid protection screen, and stabbed him in hand before fleeing the premises. He added that such attacks on pharmacists had become a "trend". Condemning the attack, Swann said: "Abuse or assaults of any kind on health and social care staff will not be tolerated. I was appalled to hear of the assault on the community pharmacist at the weekend.

What's valerian root used for? The ancient Greeks and Romans used valerian root to treat: Nausea Gas Heart pulsings Urinary tract infections Insomnia The German tribes believed it could tame the wildest of animals. They also hung it outside their homes to frighten witches and devils. Hertha, a Teutonic witch-goddess, rode a deer crowned with hops and used a stem of valerian as a lash. During the Middle Ages, astrological botanist Nicholas Culpeper simmered valerian root with raisins, licorice, and aniseed. He used the tonic to cure bubonic plague and chest congestion. In 1620, valerian root was carried to North America on the Mayflower. During World War I and II, it was used to reduce stress caused by air attacks. It was also mixed with hops and kava-kava to treat shell-shocked frontline troops. HOW DOES IT WORK? It is a powerful herb used since ancient times to help people relax and fall asleep. Valerian works by acting on the GABA (Gamma-Aminobutyric acid) receptors in your brain to induce relaxation, making it an ideal supplement for those with anxiety or insomnia who want to sleep better at night. The active compounds in valerian plants are called valepotriates, which act as sedatives at low doses and stimulants at higher doses. Valerian Uses & Effectiveness Consuming valerian root extract 300-600 mg by mouth daily appears to improve sleep quality. It is possibly effective for treating Insomnia symptoms. For notice effects, continue its usage for up to 4 weeks. There is welfare in consuming valerian for several other purposes, but it requires more reliable data to say whether it could help. It's generally used in various products containing other soothing herbs, such as hops, passion flowers, and lemon balms.

The Pharmacists' Defence Association (PDA) is supporting pharmacists in England whose employment has been impacted by the creation of new NHS structures. As a result of the 2022 Health and Care Act, Integrated Care Systems (ICSs) were established in England, and Clinical Commissioning Groups (CCGs) were closed on 1 July 2022. Each of the ICSs includes two key parts: an Integrated Care Board (ICB) and an Integrated Care Partnership (ICP). The association said: "The previous structures in England, established by the Health and Social Care Act 2012, originally had over 200 clinical commissioning groups. This number had reduced over recent years via mergers." "However, this latest shift to just 42 commissioning entities means a significant change to significantly larger geographies and populations covered by each ICS. Although each ICS and its activity can be subdivided into 'places', and within places into 'neighbourhoods', it is at the ICS level that the employer is formed." "Whereas CCGs previously employed many local health professionals, including pharmacists, the new arrangements mean that ICBs are now that employer. The PDA is supporting members who have contacted its Service Centre about the impact of these changes."

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

A survey of over six thousands pharmacies has revealed that the community pharmacy sector is buckling under growing cost and capacity pressures. The survey conducted by the Pharmaceutical Services Negotiating Committee, which also involved two thousand community pharmacy confirms, rising costs, patient demand and medicine supply issues continue to grip the sector. PSNC's 2023 Pharmacy Pressures Survey, run as a follow up to the 2022 pressures survey, provides clear comparative data showing the worsening situation across the sector. Govt must act now The result of the survey indeed paints a bleak picture for community pharmacies and it is clear that without urgent action from government and the NHS this will only get worse: more community pharmacies will either be forced to reduce the number of services they provide or, in the worst-case scenario, will be left with no option but to close their doors for good. The PSNC has urged the government to act now "to save our pharmacies, before it is too late for patients, the public, and the rest of the NHS". "This year's survey clearly shows that community pharmacies are buckling under growing cost and capacity pressures," said PSNC Chief Executive Janet Morrison.

The General Pharmaceutical Council's Investigating Committee took decisive action on March 25, 2024, by issuing a warning to Dilsha Kiran Shah, registration number: 2049787, for her conduct as Superintendent Pharmacist of Jhoots Healthcare Ltd. Miss Shah's failure to uphold the Medicines Act 1968, specifically in ensuring the proper management of medicinal products, triggered this warning. The Act mandates supervision in "keeping, preparing, and dispensing medicinal products other than those on a general sale list." Moreover, pharmacies are inspected on five principles - Governance, Staff, Premises, Services including medicines management, and Equipment and facilities to meet the right standards. The alarm was initially raised in August 2021 when a Jhoots Healthcare Ltd pharmacy branch under Miss Shah's supervision operated without a responsible pharmacist. Despite explicit instructions, pharmacy staff were allegedly instructed to proceed without proper supervision, raising grave concerns regarding patient safety.

NHS England has launched the first major update to the 'Act FAST' campaign since 2009, as new data reveals that many stroke patients wait almost an hour and a half on average before making an emergency call. The updated campaign urges the public to call 999 immediately if anyone experiences one of the three common stroke symptoms: difficulty smiling (Face), trouble raising an arm (Arms), or slurred speech (Speech). Around 100,000 people are estimated to suffer a stroke each year in the UK, which occurs when the blood supply to part of the brain is cut off. Without prompt treatment, a stroke can lead to death or long-term disabilities such as paralysis, memory loss and communication problems. Strokes remain the fourth single leading cause of death in the UK, resulting in about 38,000 deaths each year. An analysis of NHS data for 2023-24 indicated that among 41,327 patients with a recorded time of symptom onset, the average time from the first symptom to making a 999 call was 88 minutes. Additionally, a poll of 2,001 adults in England revealed that 57 per cent of respondents believed you should have 2-3 symptoms of a stroke before calling 999, despite the fact that even one symptom is a sign of a medical emergency.